Novus Ther­a­peu­tics plunges deep in­to pen­ny stock ter­ri­to­ry af­ter failed ear tri­al

Af­ter a more than 15-year run, a Cal­i­for­nia-based biotech is ex­plor­ing op­tions, in­clud­ing a sale, af­ter its lead ex­per­i­men­tal ther­a­py failed an ex­plorato­ry mid-stage study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.